Everest Organics shines on getting USFDA approval for Aroor manufacturing facility

06 Jun 2017 Evaluate

Everest Organics is currently trading at Rs. 108.15, up by 5.15 points or 5% from its previous closing of Rs. 103.00 on the BSE.

The scrip opened at Rs. 105.30 and has touched a high and low of Rs. 108.15 and Rs. 103.00 respectively.

The BSE group 'XT' stock of face value Rs. 10 has touched a 52 week high of Rs. 114.80 on 10-April-2017 and a 52 week low of Rs. 26.00 on 8-Jun-2016.

Last one week high and low of the scrip stood at Rs. 108.15 and Rs. 90.30 respectively. The current market cap of the company is Rs. 86.27 crore.

The United States Food and Drug Administration (USFDA) inspected Everest Organics’ Manufacturing Facility at Aroor Village and for the same the company has received the final approval. The USFDA has inspected the same from February 27, 2017 to March 3, 2017.

Everest Organics is engaged in the business of bulk drugs and active pharmaceutical ingredients (APIs). It is involved in manufacturing of bulk drugs, such as Omeprazole, Ciprofloxacin, Dichloroflurobenzene, Naproxen and Benzimadizole.

Everest Organics Share Price

458.25 -17.75 (-3.73%)
26-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.20
Dr. Reddys Lab 1269.05
Cipla 1505.05
Zydus Lifesciences 911.50
Lupin 2112.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×